Significant Ownership of Julian C. Baker
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Julian C. Baker focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager location
- New York, NY
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
1 identity field
Follow Filing Activity
Follow Julian C. Baker with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Julian C. Baker
Significant Ownership of Julian C. Baker
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | Common Stock, $0.0001 par value per share | 25% | $1,162,886,859 | 43,294,373 | Julian C. Baker | 24 Feb 2026 | ||
| ONC | BeOne Medicines Ltd. | Ordinary Shares, par value $0.0001 per share | 8% | $36,692,201,272 | -$1,740,708 | 115,912,814 | -0% | Julian C. Baker | 11 Jun 2026 |
| KNSA | Kiniksa Pharmaceuticals International, plc | Class A Ordinary Shares, nominal value $0.000273235 per share | 7% | $140,056,330 | 3,253,341 | Julian C. Baker | 21 May 2026 |
Schedules 13D/G Reported by Julian C. Baker:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.